This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -3.45% and 9.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?
by Zacks Equity Research
Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?
by Zacks Equity Research
Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.
Here's What Key Metrics Tell Us About Travere (TVTX) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -79.59% and 2.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere (TVTX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why
by Zacks Equity Research
Travere (TVTX) is on track to file an sNDA to the FDA to convert the accelerated approval for lead drug, Filspari, to full approval for IgAN in first-quarter 2024.
Wall Street Analysts Think Travere (TVTX) Could Surge 66.29%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 66.3% upside potential for Travere (TVTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli
by Zacks Equity Research
Mirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery.
Travere (TVTX) Up on Latest Portfolio Updates & Reorganization
by Zacks Equity Research
Travere (TVTX) to submit an sNDA to the FDA to convert the accelerated approval for Filspari to full approval for IgAN in first-quarter 2024. The company is implementing a strategic reorganization to cut costs. Stock rises.
Travere (TVTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Travere Therapeutics (TVTX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study
by Zacks Equity Research
Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval.
Xoma (XOMA) Moves 7.7% Higher: Will This Strength Last?
by Zacks Equity Research
Xoma (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why
by Zacks Equity Research
Mirum Pharma (MIRM) surges 42% year to date due to encouraging progress in label-expansion efforts of Livmarli, along with strategic initiatives, to expand its commercial portfolio.
Travere (TVTX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of 2.59% and 10.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -7.63% and 11.90%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Meets Q3 Earnings Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 0% and 0.74%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?